CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines The Prevalence of Myocardial Bridging Associated with Coronary Endothelial Dysfunction in Patients with Chest Pain and Non-Obstructive Coronary Artery Disease Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA) Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT When, where, and how to target vascular inflammation in the post-CANTOS era? Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Guideline31 August 2019

JOURNAL:Eur Heart J. Article Link

2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD ESC Clinical Practice Guidelines

F Cosentino, PJ Grant, ESC Scientific Document Group et al. Keywords: guidelines; diabetes mellitus; impaired glucose tolerance; cardiovascular diseases; epidemiology; risk factors; prevention; cardiovascular risk assessment; patient management; pharmacological treatment; revascularization; patient-centred care

FULL TEXT PDF